1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial. (linkinghub.elsevier.com)

Authors: Sotomi Y … Sakata Y Journal: The Lancet Published: 2026-07-15 DOI: https://doi.org/10.1016/S0140-6736(26)00665-3